lunes, 30 de abril de 2012

A David Brennan le dieron AZ_ote...

As it posted disappointing sales and earnings for the first quarter, AstraZeneca has announced that chief executive David Brennan is to retire, amid pressure from disgruntled shareholders.

Mr Brennan (pictured) will be replaced by chief financial officer Simon Lowth from June 1 on an interim basis. It was also revealed that Leif Johansson will succeed Louis Schweitzer as non-executive chairman three months earlier than previously announced, in order to lead the selection process for Mr Brennan’s successor "including both internal and external candidates".

Mr Brennan's decision has come as something of a surprise given that just a week ago, he was reported as saying that he was "plugged in" as boss, despite rumours that a number of major shareholders had questioned whether he was the man to lead the company as it battles to deal with several recent pipeline setbacks. However, he now says that "after more than six years as CEO of this great company, I have decided that now is the right time to step down and allow a new leader to take the reins".

Mr Schweitzer said: “David has led AstraZeneca’s business with skill, integrity and courage during a period of enormous change for the pharmaceutical industry and for the company". He added that "we fully understand and respect David’s decision to retire and thank him for his selfless leadership".


Ver tambien.

AstraZeneca appoints Spencer Stuart to find new CEO

No hay comentarios: